Miraculins amends private placement offering

Miraculins (TSX-V:MOM) has raised the number of units in a previously announced private placement to 10 million from 7.5 million, with the units priced at five cents each instead of seven cents, for gross proceeds of $500,000. Each unit will consist of one common share of the company and one warrant.  Each warrant can be [...]

In conversation with Bruce Brydon

As the CEO of closely held Trimel BioPharma Inc., Bruce Brydon has been down this road before.  For one thing, he ran Biovail for nearly eight years during its glory days from 1994 until mid-2002 for major shareholder, Eugene Melnyk.  When Mr. Melnyk asked his former CEO to come out of retirement a couple of [...]

ArcticDx develops next generation DNA test for AMD

ArcticDx has licensed exclusive world-wide commercial rights to a causative mutation in the HTRA1/ARMS2 gene from Regensberg University in Germany and screening for this important genetic variation has been incorporated into a next-generation version of Macula-Risk. Macula-Risk is the company’s DNA test that is intended as a prognostic test for patients who have been diagnosed [...]

Migenix closes plan of arrangement

Migenix (TSX:MGI) has closed its plan of arrangement, receiving $4 million from Madison Pacific Properties and transferring substantially all of its operations to subsidiary BioWest Therapeutics. BioWest is expected to begin trading on Wednesday under the symbol BWE, when shares of Migenix will be delisted.  The plan was approved by shareholders and the British Columbia [...]

RBC Capital Markets raises Paladin price target

Calling Paladin Labs’ (TSX:PLB) investment in Pharmaplan of South Africa an “attractive entrance into a new market,” RBC Capital Markets raised its 12-month price target on Paladin’s stock to $24 from $23. RBC rates the stock “outperform, above average risk.” Analyst Doug Miehm writes that Paladin paid $15.9 million for its initial 34.99% stake and [...]

FDA to review Ondine Periowave system

Shares of Ondine Biopharma (TSX:OBP) more than doubled in early trading after the company said the FDA formally accepted its filing for premarket approval of the Periowave photodisinfection system for the treatment of chronic periodontitis in adults as an adjunct to standard methods of care. The FDA’s action means that the PMA application is sufficiently [...]

Stellar posts profit on higher sales in 2009

Citing higher sales of its two drugs, Stellar Pharmaceuticals (OTCBB: SLXCF) posted a profit of $238,924 or 1 cent a share for 2009, compared with a year earlier loss of $31,066, and said 2009 was the third consecutive year that it was cash flow positive. Revenue rose nearly 40% to $3.6 million from $2.6 million [...]

Paladin buys stake in South African drug company

In its second swing outside of Canada this month, Paladin Labs (TSX:PLB) has acquired an initial 34.99% interest in Pharmaplan Pty. Ltd. of South Africa and has committed to increase its ownership position over time based on a formula linked to Pharmaplan’s actual financial performance, all payable in cash. Terms of the transaction weren’t disclosed [...]

Tekmira and Pfizer in research collaboration

Tekmira Pharmaceuticals (TSX:TKM) has initiated a new research collaboration with Pfizer to evaluate Tekmira’s stable nucleic acid-lipid particle (SNALP) technology to deliver small interfering RNA molecules provided by Pfizer (NYSE:PFE). This is Tekmira’s first formal research collaboration with Pfizer. Tekmira will be responsible for preparing the SNALP formulations and Pfizer will evaluate the formulations in [...]

Medicago in vaccine MOU in Japan

Medicago (TSX-V: MDG) has signed a memorandum of understanding with Japan’s NITT Partners to discuss and negotiate an agreement to commercialize Medicago’s pandemic and seasonal influenza VLP-based vaccines in Japan and other territories. For several years, NITT Partners has been the government-approved technology transfer/licensing organization to license-in state of the art technologies. Under the terms [...]

« Previous Page — Next Page »